Hua Yang1, Lemeng Zhang1, Mingwei Li2, Huina Wang2 and Jianhua Chen1*
1Department of Thoracic Internal Medicine, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya Medical School of Central South University, People's Republic of China 2Acornmed Biotechnology Co., People's Republic of ChinaFulltext PDF
Background: Uncommon mutations account for 10% to 15% of Epidermal Growth Factor Receptor (EGFR) mutations in patients with Non-Small Cell Lung Cancer (NSCLC). However, limited clinical evidence is available on the efficacy of EGFR tyrosine kinase inhibitors in patients with NSCLC harboring these uncommon EGFR mutations. Case Report: Here we report a 74-year-old man was diagnosed with stage IV lung adenocarcinoma by bronchoscopic biopsy to the left principal bronchus lung tumor. A novel EGFR p.G735R (c.2203G>C) mutation in exon 19 was detected by gene sequencing. The patient received first-line Gefitinib but primary resistance was noted with rapid tumor progression. Conclusion: Our case suggests that G735R may be one of the EGFRTKI primary resistant rare EGFR mutations.
NSCLC; EGFRG735R mutation; Gefitinib treatment; Primary resistance
Yang H, Zhang L, Li M, Wang H, Chen J. A Rare Epidermal Growth Factor Receptor G735R Mutation in Advanced Non-Small-Cell Lung Cancer with Poor Response to Gefitinib. Ann Clin Case Rep. 2021; 6: 1984..